Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Autolus Therapeutics Plc ADR (NQ: AUTL )

3.270 +0.170 (+5.48%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Autolus Therapeutics Plc ADR

< Previous 1 2 3 4 5 6 Next >
Allogene Craters To 52-Week Low On FDA Clinical Hold Of CAR-T Trials, Drags Peers As Well
The FDA has sent shockwaves through the off-the-shelf CAR-T space after it slapped a clinical hold on all of the Allogene Therapeutics Inc (NASDAQ: ALLO)... 
Via Benzinga
Exposures Product Safety
Autolus' Blood Cancer CAR T-Cell Therapy Receives Promising Innovative Medicine In UK
The U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has granted Promising Innovative Medicine (PIM) designation to Autolus Therapeutics plc's... 
Via Benzinga
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Xenetic Biosciences (NASDAQ:XBIO) stock increased by 35.01% to $5.5 during Monday's regular session. Trading volume for Xenetic Biosciences's stock is 10.1... 
Via Benzinga
Here's Why Autolus Therapeutics Is Surging Today
Potential licensing agreements with Moderna are giving investors reasons to cheer. 
Via The Motley Fool
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
Exposures Product Safety
Autolus Stock Jumps On Cancer mRNA Therapeutics Agreement With Moderna
Autolus Therapeutics plc (NASDAQ: AUTL) has granted Moderna Inc (NASDAQ: MRNA) an exclusive license to develop and commercialize mRNA therapeutics... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Exicure (NASDAQ:XCUR) stock moved upwards by 35.55% to $1.83 during Monday's pre-market session. The company's market cap stands at $161.0 million.... 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Reshape Lifesciences (NASDAQ:RSLS... 
Via Benzinga
Autolus Therapeutics' CAR T Cell Achieves 100% Complete Remission In Indolent B Cell Non-Hodgkin Cohort
Autolus Therapeutics plc (NASDAQ: AUTL) has announced new data from AUTO1 (obecabtagene autoleucel, obe-cel) in relapsed / refractory (r/r) indolent B cell... 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Sio Gene Therapies (NASDAQ:SIOX) ... 
Via Benzinga
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results.... 
Via Benzinga
Exposures Product Safety
The Week Ahead In Biotech: Biogen, Alexion And Vertex FDA Decisions, Multiple Conference Presentations On The Deck
Biopharma stocks advanced in the truncated week ended June 4 amid the broader market strength. The American Society for Clinical Oncology meeting got underway during the week,... 
Via Benzinga
Exposures Product Safety
Why Autolus Therapeutics Stock Skyrocketed Today
The company announced encouraging clinical trial data for its experimental cell therapy, AUTO1. 
Via The Motley Fool
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Curis (NASDAQ:CRIS) shares moved upwards by 57.23% to $15.46 during Wednesday's regular session. Trading volume for Curis's stock is 28.8 million as of 12:... 
Via Benzinga
62 Biggest Movers From Yesterday
Gainers Curis, Inc. (NASDAQ: CRIS) shares surged 65.5% to settle at $16.27 on Wednesday in reaction to updated data from its ongoing open-label, single-arm, Phase 1/2 study of CA... 
Via Benzinga
40 Stocks Moving In Wednesday's Mid-Day Session
Gainers Ra Medical Systems, Inc. (NASDAQ: RMED) shares jumped 76% to $5.84 after the company reported better-than-expected Q1 results. Lucira Health, Inc. (NASDAQ: LHDX) gained... 
Via Benzinga
The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11) HOOKIPA Pharma Inc. (NASDAQ... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 10) AbbVie Inc. (NYSE: ABBV) -... 
Via Benzinga
Exposures COVID-19 Product Safety
The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 6) GT Biopharma, Inc. (NASDAQ:... 
Via Benzinga
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.